alexa Chickenpox | Israel | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences

Read more

Recommended Journals

Relevant Topics

Chickenpox

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Chickenpox

    Chicken Pox
    Chickenpox is a highly contagious viral infection in which a person develops extremely itchy blisters all over the body and it is common childhood disease caused by a virus in the herpes family of viruses called the varicella virus. The varicella virus can remain in the body for decades and become active again in adults, causing herpes zoster (shingles). Shingles involves the occurrence of painful skin sores along the distribution of nerves across the trunk or face.

  • Chickenpox

    Symptoms
    Itchy blisters on a red base, progressing to scabs, appear along with newer blisters, mainly on the trunk, face, and scalp and last 5 to 10 days. Other symptoms include fever, headache, tiredness and loss of appetite.The chickenpox rash occurs about 10 to 21 days after coming into contact with someone who had the disease. The average child develops 250 to 500 small, itchy, fluid-filled blisters over red spots on the skin.

  • Chickenpox

    Prevention
    Chickenpox vaccine is very safe and effective at preventing the disease. Most people who get the vaccine will not get chickenpox. If a vaccinated person does get chickenpox, it is usually mild—with fewer blisters and mild or no fever. The chickenpox vaccine prevents almost all cases of severe disease.

  • Chickenpox

    Statistics
    In Isreal incidence rates fluctuated around 10 cases per 10,000 soldiers without a clear trend. Military conscipts aged 18–21 comprised 78% of the study population (male 53%, female 25%) and career personnel aged 22–45 represented 22% (male 19%, female 3%). A seroepidemiological study performed in Israel between the years 2000–2001 discovered varying seropositivity rates across age categories. While the overall rate of seropositives was 90.2%, this proportion increased with age from 68.9% at age 4 to 96.6% at age Another seroprevalence study in Israel conducted in 2003 among 536 military recruits at age 18 y found a seroprevalence of 94.6%.

 

High Impact List of Articles

Conference Proceedings